Combination therapies utilizing benzamide inhibitors of the P2X7 receptor
    6.
    发明申请
    Combination therapies utilizing benzamide inhibitors of the P2X7 receptor 审中-公开
    使用P2X7受体的苯甲酰胺抑制剂的组合疗法

    公开(公告)号:US20060018904A1

    公开(公告)日:2006-01-26

    申请号:US11168602

    申请日:2005-06-28

    摘要: This invention provides methods of treatment of IL-1 mediated diseases comprising administering a pharmaceutically effective amount of a pharmaceutical agent selected from the group of sulfasalazine, a statin, a glucocorticoid agent, an inhibitor of p38 kinase, an anti-IL-6-receptor antibody, anakinra, an IL-1 monoclonal antibody, an inhibitor of JAK3 protein tyrosine kinase, a M-CSF monoclonal antibody or a humanized anti-CD20 monoclonal antibody and a benzamide inhibitor of the P2X7 receptor of the formula: wherein R1-R3 are as defined herein. The methods of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

    摘要翻译: 本发明提供了治疗IL-1介导的疾病的方法,其包括施用药学有效量的选自下组的药剂:柳氮磺吡啶,他汀类,糖皮质激素药,p38激酶抑制剂,抗IL-6受体 抗体,阿那酸,IL-1单克隆抗体,JAK3蛋白酪氨酸激酶抑制剂,M-CSF单克隆抗体或人源化抗CD20单克隆抗体,以及P2X 7受体的苯甲酰胺抑制剂 其中R 1〜R 3如本文所定义。 本发明的方法可用于治疗IL-1介导的病症,包括但不限于炎性疾病如骨关节炎和类风湿性关节炎; 过敏,哮喘,COPD,癌症,中风或心脏病发作中的再灌注或缺血,自身免疫疾病和其他疾病。